Biotech investors are preparing for what may be the most important clinical trial readout for them this summer.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The consistent outperformance in multiple forms of administration against multiple existing standards of care is certainly very bullish for Summit, whose stock is nearly all the way back to an ...

We recently published a list of These 10 Firms Soared Last Week, Here’s Why. In this article, we are going to take a look at ...

Summit Therapeutics PLC (SMMT) closed the last trading session at $28.02, gaining 61.8% over the past four weeks, but there ...

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of ...

Summit Therapeutics shares rallied after its lung cancer drug candidate showed that it improved patients' longevity without the disease worsening in a late-stage trial. Shares of Summit rose 11% ...

The latest price target for Summit Therapeutics (NASDAQ:SMMT) was reported by Goldman Sachs on May 2, 2025. The analyst firm set a price target for $41.00 expecting SMMT to rise to within 12 ...

Summit Therapeutics (NASDAQ: SMMT) has more than just a potential blockbuster cancer drug in its portfolio. Ivonescimab could be one of the best drugs to ever hit the market. This has investors ...

In this article, we are going to take a look at where Summit Therapeutics Inc. (NASDAQ:SMMT) stands against other firms that soared last week. The past trading week saw a more calm, generally ...